Zymeworks (ZYME) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$37.1M

Revenue (quarter)

$4.6M

Revenue growth (year over year)

−90.58%

Gross profit (trailing twelve months)

$37.1M

Gross margin

100.00%

Net income (trailing twelve months)

−$150.0M

Net income (quarter)

−$45.0M

Net income growth (year over year)

−2042.99%

Net margin

−404.00%

Return on equity

−72.31%

EPS (trailing twelve months)

−$2.02

Book value per share

$1.13

P/E (trailing twelve months)

—

Price to book

22.36

Debt to assets

79.75%

Payout ratio

—

Dividend yield

—

Company profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

• Is Zymeworks (ZYME) profitable?

  No. Zymeworks reported a net loss of $150.0M over the trailing twelve months.

• How much revenue does Zymeworks (ZYME) make?

  Zymeworks generated $37.1M in revenue over the trailing twelve months, down 90.58% year over year.

• How do I buy stock in Zymeworks (ZYME)?

  ZYME trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.